SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

24 Jul 2025 Evaluate
Revenue showed a marginal decline at Rs. 3925.30 millions. For the quarter ended June 2025, as compared to corresponding quarter of last year.The Net Loss for the quarter ended June 2025 is Rs. -280.60 millions as compared to Net Profit of Rs. 149.50 millions of corresponding quarter ended June 2024The Operating Profit of the company witnessed a decrease to 204.10 millions from 550.90 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 3925.30 4014.30 -2.22 3925.30 4014.30 -2.22 15181.90 17908.10 -15.22
Other Income 55.80 35.20 58.52 55.80 35.20 58.52 184.80 85.10 117.16
PBIDT 204.10 550.90 -62.95 204.10 550.90 -62.95 1465.20 2664.90 -45.02
Interest 236.10 118.80 98.74 236.10 118.80 98.74 566.30 368.20 53.80
PBDT -32.00 432.10 -107.41 -32.00 432.10 -107.41 908.80 2412.00 -62.32
Depreciation 252.00 237.00 6.33 252.00 237.00 6.33 982.50 879.80 11.67
PBT -284.00 195.10 -245.57 -284.00 195.10 -245.57 -73.70 1532.20 -104.81
TAX -3.40 45.60 -107.46 -3.40 45.60 -107.46 13.60 365.80 -96.28
Deferred Tax -3.40 -1.70 100.00 -3.40 -1.70 100.00 13.60 38.10 -64.30
PAT -280.60 149.50 -287.69 -280.60 149.50 -287.69 -87.30 1166.40 -107.48
Equity 184.50 184.40 0.05 184.50 184.40 0.05 184.50 184.40 0.05
PBIDTM(%) 5.20 13.72 -62.11 5.20 13.72 -62.11 9.65 14.88 -35.15

Indoco Remedies Share Price

221.30 -6.90 (-3.02%)
11-May-2026 14:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1290.10
Cipla 1309.20
Zydus Lifesciences 953.80
Lupin 2280.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×